

3 March 2026

## **Treatment of Waldenström macroglobulinaemia (WM) & Marginal zone lymphoma (MZL)**

### **1. Does your Trust treat patients for the two following conditions?**

**Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)  
Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)**

Yes

**If yes:**

#### **1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?**

##### **Waldenström macroglobulinaemia (WM)**

Data collated from Slicer Dicer on Encompass 01/01/25 to 31/12/25 selecting Department as Belfast Trust Haematology Clinics / Treatment

Diagnosis code (C88.0) = 42 patients.

##### **Marginal zone lymphoma (MZL)**

Data collated from Slicer Dicer on Encompass 01/01/25 to 31/12/25 selecting Department of Belfast Trust Haematology Clinics / Treatment

Diagnosis code (C83.0) = 19 patients

Diagnosis code (C88.4) = 15 patients.

#### **1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials?**

**Waldenström macroglobulinaemia (WM)  
Marginal zone lymphoma (MZL)**

There are no ongoing clinical trials running at Belfast Trust for these conditions.

3 March 2026

Please skip 1c to question 2 and 3.

If no:

1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

2. How many patients (and new patients\* if possible) received treatment for:

Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)		
Regimen	Total Patients	New Patients*
Fludarabine, cyclophosphamide and rituximab (Known as FCR)	0	0
Bendamustine in combination with rituximab (Known as BR)	<5	<5
Ibrutinib	7	0
Ibrutinib in combination with rituximab	0	0
Zanubrutinib	9	<5
Acalabrutinib	0	0
Chemotherapy (Other than the listed regimens)	<5	<5
Wait and watch - no active treatment and monitoring only	21	0
Any other treatment (Other than the listed regimens)	0	0

**\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.**

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

3 March 2026

**3. How many patients (and new patients\* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?**

<b>Marginal zone lymphoma (MZL) (ICD-10 C83.0 &amp; C88.4)</b>		
<b>Regimen</b>	<b>Total Patients</b>	<b>New Patients*</b>
Bendamustine in combination with rituximab (Known as BR)	0	0
Chlorambucil in combination with rituximab (Known as CR)	<5	<5
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)	<5 (mini)	<5
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)	0	0
Zanubrutinib	7	5
Stem Cell Transplant	0	0
Wait and watch - no active treatment and monitoring only	22	0
Any other treatment (Other than the listed regimens)	<5	<5

**\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.**

**NOTE:**

Information provided for Questions 2 and 3 was manually collated from individual patient's charts on EPIC and has not been officially verified.